Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Scaldaferri F, Di Vincenzo F, Aloi M, Ascolani M, Balestrieri P, Bertani L, Bezzio C, Bodini G, Bossa F, Calabrese E, Cannatelli R, Caprioli F, Cappello M, Cicala M, D'Amico F, Danese S, De Bernardi A, De Filippo FR, Desideri F, Di Paolo D, Di Sario A, Fantini MC, Ferracane C, Festa S, Fiorino G, Gabbiadini R, Geccherle A, Gerardi V, Giangreco E, Gravina AG, Laterza L, Lopetuso LR, Marafini I, Mastronardi M, Mendolaro M, Merli M, Mocci G, Onali S, Onidi MF, Pastorelli L, Piagnani A, Principi MB, Pugliese D, Ribaldone DG, Rispo A, Rizzello F, Santagata F, Savarino EV, Spagnuolo R, Tursi A, Panarese A, Mazzuoli S, Variola A, Viganò C, Armuzzi A, RESOLVE Study Group

Open source

DOI: 10.14309/ajg.0000000000003969
Published: 2026 Feb 18
Container: The American journal of gastroenterology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.14309/ajg.0000000000003969,
  title = {Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.},
  author = {Scaldaferri F and Di Vincenzo F and Aloi M and Ascolani M and Balestrieri P and Bertani L and Bezzio C and Bodini G and Bossa F and Calabrese E and Cannatelli R and Caprioli F and Cappello M and Cicala M and D'Amico F and Danese S and De Bernardi A and De Filippo FR and Desideri F and Di Paolo D and Di Sario A and Fantini MC and Ferracane C and Festa S and Fiorino G and Gabbiadini R and Geccherle A and Gerardi V and Giangreco E and Gravina AG and Laterza L and Lopetuso LR and Marafini I and Mastronardi M and Mendolaro M and Merli M and Mocci G and Onali S and Onidi MF and Pastorelli L and Piagnani A and Principi MB and Pugliese D and Ribaldone DG and Rispo A and Rizzello F and Santagata F and Savarino EV and Spagnuolo R and Tursi A and Panarese A and Mazzuoli S and Variola A and Viganò C and Armuzzi A and RESOLVE Study Group},
  year = {2026},
  journal = {The American journal of gastroenterology},
  doi = {10.14309/ajg.0000000000003969},
  url = {https://doi.org/10.14309/ajg.0000000000003969}
}

RIS

TY  - JOUR
TI  - Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.
AU  - Scaldaferri F
AU  - Di Vincenzo F
AU  - Aloi M
AU  - Ascolani M
AU  - Balestrieri P
AU  - Bertani L
AU  - Bezzio C
AU  - Bodini G
AU  - Bossa F
AU  - Calabrese E
AU  - Cannatelli R
AU  - Caprioli F
AU  - Cappello M
AU  - Cicala M
AU  - D'Amico F
AU  - Danese S
AU  - De Bernardi A
AU  - De Filippo FR
AU  - Desideri F
AU  - Di Paolo D
AU  - Di Sario A
AU  - Fantini MC
AU  - Ferracane C
AU  - Festa S
AU  - Fiorino G
AU  - Gabbiadini R
AU  - Geccherle A
AU  - Gerardi V
AU  - Giangreco E
AU  - Gravina AG
AU  - Laterza L
AU  - Lopetuso LR
AU  - Marafini I
AU  - Mastronardi M
AU  - Mendolaro M
AU  - Merli M
AU  - Mocci G
AU  - Onali S
AU  - Onidi MF
AU  - Pastorelli L
AU  - Piagnani A
AU  - Principi MB
AU  - Pugliese D
AU  - Ribaldone DG
AU  - Rispo A
AU  - Rizzello F
AU  - Santagata F
AU  - Savarino EV
AU  - Spagnuolo R
AU  - Tursi A
AU  - Panarese A
AU  - Mazzuoli S
AU  - Variola A
AU  - Viganò C
AU  - Armuzzi A
AU  - RESOLVE Study Group
PY  - 2026
JO  - The American journal of gastroenterology
DO  - 10.14309/ajg.0000000000003969
UR  - https://doi.org/10.14309/ajg.0000000000003969
ER  -

APA

F, S., F, D. V., M, A., M, A., P, B., L, B., C, B., G, B., F, B., E, C., R, C., F, C., M, C., M, C., F, D., S, D., A, D. B., FR, D. F., F, D., D, D. P., A, D. S., MC, F., C, F., S, F., G, F., R, G., A, G., V, G., E, G., AG, G., L, L., LR, L., I, M., M, M., M, M., M, M., G, M., S, O., MF, O., L, P., A, P., MB, P., D, P., DG, R., A, R., F, R., F, S., EV, S., R, S., A, T., A, P., S, M., A, V., C, V., A, A., & Group, R. S. (2026). Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.. The American journal of gastroenterology. https://doi.org/10.14309/ajg.0000000000003969

Source records

pubmed · retrieved 2026-09-27T12:10:53.946Z